Preferential treatment for orphan drugs is very much in play overseas. Pricing guru Jack Mycka, VP in the PRMA (pricing, reimbursement, market access) division of Indegene, explains what potential European reforms could mean for pharma marketers in light of U.S. pressure to reform drug pricing.
MM+M Podcast 6.14.22: Why Europe wants to close the orphan drug loophole
Preferential treatment for orphan drugs is very much in play overseas. Jack Mycka, VP in the PRMA division of Indegene, explains what potential European reforms could mean for pharma marketers.
